AbCellera Biologics (ABCL) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and AbCellera published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• AbCellera is based in Vancouver and files 10-Q and 10-K reports with the SEC, in U.S. dollars.
• AbCellera's results include an income tax recovery and grants and incentives income; in Q3 2026 these were $2.1 million and $3.6 million.

Source: AbCellera Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How AbCellera splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• AbCellera's Research fees revenue was $10.5 million in Q3 2026, up 20% from $8.8 million in Q3 2025, 99% of total revenue.
• AbCellera's Licensing and royalty revenue revenue was $0.1 million in Q3 2026, down 35% from $0.1 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and net loss per share, each as first reported. Q4 2025 revenue is the 2025 annual figure less the first nine months; AbCellera's Q4 2025 release gave full-year per-share results only, so Q4 2025 EPS is left blank.

We do not hold a confirmed date for AbCellera's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

AbCellera earns revenue from antibody discovery work for partners, not from product sales. Total revenue was $10.6 million in Q3 2026, against $9.0 million a year earlier: research fees of $10.5 million, up 20%, and licensing and royalty revenue of $90 thousand. (AbCellera Q3 2026 release, Nov 9, 2026; AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

Two new T-cell engager collaborations will feed research fees. Jazz Pharmaceuticals paid $56.0 million upfront in the second quarter of 2026 for two research programs, with another $28.0 million due if a third starts, and Vertex paid $28.0 million upfront during Q3 2026 for two programs. AbCellera recognizes these as it performs the research and expects them to lift research fee revenue in future periods. (AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

Over the first nine months of 2026 revenue fell 24% to $23.0 million, because licensing revenue recognized in the second quarter of 2025 did not recur. Licensing and royalty revenue was $431 thousand for the nine months, against $10.8 million a year earlier. (AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

AbCellera says most of the value in its partner contracts is in downstream milestones and royalties. At the end of Q3 2026 partners led 34 programs in which it holds a downstream stake, down from 44 at December 31, 2025, and it held stakes in 12 molecules in the clinic. (AbCellera Q3 2026 release, Nov 9, 2026; AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

AbCellera reports GAAP results only. Its net loss narrowed to $40.8 million, or $0.13 per share, from $57.1 million, or $0.19 per share. Research and development expense fell to $43.5 million from $55.0 million, and sales, general and administrative expense fell $11.3 million, or 45%, to $13.6 million. (AbCellera Q3 2026 release, Nov 9, 2026; AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

Other income and taxes cushion the operating loss of $53.3 million: interest and other income of $6.9 million, grants and incentives of $3.6 million and an income tax recovery of $2.1 million, against an $11.6 million recovery a year earlier. (AbCellera Q3 2026 release, Nov 9, 2026)

In August 2026 AbCellera sold 17,435,897 common shares at $9.75 and pre-funded warrants for 3,076,926 shares, for gross proceeds of about $200.0 million and net proceeds of $188.8 million. Weighted-average shares were 318,053,142 in Q3 2026, against 298,875,174 a year earlier. (AbCellera Q3 2026 release, Nov 9, 2026; AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

AbCellera gives no revenue or EPS guidance in its release. It reports total cash, cash equivalents and marketable securities of over $790 million and total available liquidity of over $890 million, including over $100 million of available non-dilutive government funding. (AbCellera Q3 2026 release, Nov 9, 2026)

After positive Phase 2 data for ABCL635, an NK3R antagonist antibody for moderate and severe hot flashes, AbCellera expects to start late-stage development for menopausal vasomotor symptoms in 2027 and trials in hot flashes caused by breast and prostate cancer treatment in 2027. It does not plan to develop ABCL575 past Phase 1. (AbCellera Q3 2026 release, Nov 9, 2026; AbCellera Form 10-Q, Q3 2026, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover AbCellera, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones AbCellera's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ABCL is on is ABCL a buy or a sell?, what analysts expect next is on the ABCL forecast, and what the company does is on the AbCellera Biologics (ABCL) stock page.

Every number on this page can be traced to a document AbCellera published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.